Subtle Medical gets CE Mark for SubtlePET 2.0

AuntMinnieEurope.com staff writers
Jun 8, 2021
2021 05 04 17 40 9512 Computer Doctor 400

Medical image software developer Subtle Medical has been granted the CE Mark for the second generation of its SubtlePET software, which removes noise to improve low-count PET image quality.

Also, the software now can be used with radiopharmaceuticals that target prostate-specific membrane antigen (PSMA) expression and neuroendocrine tumors. The software is vendor-neutral and can be used with any company's PET and PET/CT equipment.

Latest in Molecular Imaging
Parizel is the David Hartley chair of radiology at the University of Western Australia (UWA) in Perth.
Parizel makes compelling case for collaboration
April 16, 2024
Fapi Lung Cancer
FAPI-PET shows promise in patients with lung cancer
April 16, 2024
Cushing Disease
PET/MRI may improve diagnosis of Cushing disease
April 1, 2024
Lld
PET/MRI displays promise in patients with late-life depression
March 25, 2024
Related Stories
2021 09 14 23 49 7847 Business Handshake 400
Artificial Intelligence
Getz Healthcare, Subtle Medical sign distribution deal
2021 11 28 20 00 6152 Siemens Rsna 2021 400
Industry News
Subtle's software integrated into Siemens' Open Recon
2019 12 19 00 53 5252 Hands Shaking Deal 400
Artificial Intelligence
Unilabs secures deal with Subtle Medical on AI tool
2021 09 14 23 49 7847 Business Handshake 400
Artificial Intelligence
Aidoc joins forces with Subtle Medical
More in Molecular Imaging
Parizel makes compelling case for collaboration
By Philip Ward
It's time for radiology and nuclear medicine to bury their differences, says former European Society of Radiology president Prof. Paul Parizel, PhD. In a Q&A interview, he also speaks about contrast media shortages in CT and life in Perth, Australia.
April 16, 2024
Parizel is the David Hartley chair of radiology at the University of Western Australia (UWA) in Perth.
FAPI-PET shows promise in patients with lung cancer
By Will Morton
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to German researchers.
April 16, 2024
Fapi Lung Cancer
PET/MRI may improve diagnosis of Cushing disease
By Will Morton
PET/MRI could become the diagnostic method of choice over MRI alone for identifying small pituitary tumors associated with Cushing disease.
April 1, 2024
Cushing Disease
PET/MRI displays promise in patients with late-life depression
By Will Morton
PET/MRI scans have revealed positive findings for patients with late-life depression – namely that they have preserved “synaptic density,” and thus are likely to respond to treatment, Belgian researchers have reported.
March 25, 2024
Lld
Serac highlights SPECT/CT study in women with endometriosis
By AuntMinnieEurope.com staff writers
Serac Healthcare has highlighted preliminary findings that suggest its SPECT/CT technetium-99m (Tc-99m) maraciclatide radiotracer can help detect endometriosis at an early stage of the disease.
March 20, 2024
Serac
FAPI-PET/CT outperforms FDG-PET/CT in women with invasive breast cancer
By Will Morton
PET/CT imaging using gallium-68 FAPI radiotracer over F-18 FDG appears promising in women with invasive lobular carcinoma.
March 19, 2024
Fapi Ilc
Nobel Prize for PET? Fireside chat with Hans Ringertz
By Philip Ward
Are we getting close to a Nobel Prize for clinical PET imaging? What does the ECR 1997 president make of ECR 2024? And should the next generation of radiologists subspecialize? We interview Prof. Hans Ringertz, an iconic figure in global radiology.
March 8, 2024
2024 03 07 Ringertz Ecr Interview
Is ‘theragnomics’ the future in molecular imaging?
By Will Morton
Combining theranostics and radiomics – a new concept termed “theragnomics” – could be the key to realizing the full potential of molecular imaging of cancer patients.
March 6, 2024
Molecular Imaging
Viennese team presents novel findings on NSCLC patients
By Edna Astbury-Ward, PhD
Austrian researchers have found neoadjuvant chemoimmunotherapy leads to a high rate of pathologic complete remissions in cases of early-stage, non-small cell lung cancer (NSCLC).
February 22, 2024
Radiological response inconsistent with pathological response: 69-year-old patient with non-small cell lung cancer (NSCLC) received a neoadjuvant treatment with three cycles of immune-checkpoint inhibitor therapy plus chemotherapy (ICIT + C, carboplatin/pemetrexed/pembrolizumab). 12 weeks after treatment began, the patient showed complete pathologic response (ypTo, pNo) but only partial radiological response.
Was nuclear medicine adequately consulted on new guidelines?
By Liz Carey
Nuclear medicine physicians have warned of gaps and errors in recommendations for the management of thyroid nodules. They claim they weren't involved enough in the discussion stages.
February 19, 2024
Thyroid 400
Life Molecular and Oryx sign deal to distribute amyloid PET tracer
By AuntMinnie.com staff writers
Life Molecular Imaging has established a partnership with Oryx Isotopes Industrial Company to produce and distribute Neuraceq in Saudi Arabia.
February 7, 2024
Pet Scanner Bore 400
How are clinical staff using ChatGPT at the Charité in Berlin?
By Liana Gruenberg
Dr. Julian Rogasch and his colleague Dr. Imke Schatka explain to Liana Gruenberg about the current and future potential of the ChatPPT AI tool and how it's being used clinically at the world-famous Charité.
February 2, 2024
2024 01 26 Rogasch And Gruenberg
Page 1 of 115
Next Page